[
  {
    "ts": null,
    "headline": "ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK",
    "summary": "WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. between February 3, 2022 and February 3, 2025, both dates inclusive , of the important...",
    "url": "https://finnhub.io/api/news?id=1c69e03f62a171f50390bc0ca917ea9d4b4e5cbf860a3f0749d2ff8269733dcd",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742410383,
      "headline": "ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK",
      "id": 133262811,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. between February 3, 2022 and February 3, 2025, both dates inclusive , of the important...",
      "url": "https://finnhub.io/api/news?id=1c69e03f62a171f50390bc0ca917ea9d4b4e5cbf860a3f0749d2ff8269733dcd"
    }
  },
  {
    "ts": null,
    "headline": "Why Merck & Co. (MRK) Is Among the Most Undervalued Biotech Stocks to Invest In",
    "summary": "We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other most undervalued biotech stocks to invest in. Trump’s Tariffs and the Pharma Sector On February 21, Jared Holz, Mizuho […]",
    "url": "https://finnhub.io/api/news?id=28dd2e1cb1b2c0f2c420d8fddcfbf502b5108aebc3962967ef9ac3ec19c00ea9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742395539,
      "headline": "Why Merck & Co. (MRK) Is Among the Most Undervalued Biotech Stocks to Invest In",
      "id": 133324747,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other most undervalued biotech stocks to invest in. Trump’s Tariffs and the Pharma Sector On February 21, Jared Holz, Mizuho […]",
      "url": "https://finnhub.io/api/news?id=28dd2e1cb1b2c0f2c420d8fddcfbf502b5108aebc3962967ef9ac3ec19c00ea9"
    }
  },
  {
    "ts": null,
    "headline": "Managing Risk Through Market Badness With Rob Isbitts",
    "summary": "Rob Isbitts explains how investors should manage risk in the midst of volatile markets.",
    "url": "https://finnhub.io/api/news?id=143f44fcf015ea6701f41fd14bd663b6f70d31e762641ef3773834d1cb5d4185",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742395500,
      "headline": "Managing Risk Through Market Badness With Rob Isbitts",
      "id": 133260531,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1023759644/image_1023759644.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Rob Isbitts explains how investors should manage risk in the midst of volatile markets.",
      "url": "https://finnhub.io/api/news?id=143f44fcf015ea6701f41fd14bd663b6f70d31e762641ef3773834d1cb5d4185"
    }
  },
  {
    "ts": null,
    "headline": "Merck Loses Almost $52B in 6 Months: How to Play MRK Stock",
    "summary": "We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.",
    "url": "https://finnhub.io/api/news?id=8ceafd18b9e0a5a012c58f90a781c826b7b5afa47a10a9dcda217badb369f2b2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742393460,
      "headline": "Merck Loses Almost $52B in 6 Months: How to Play MRK Stock",
      "id": 133324748,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.",
      "url": "https://finnhub.io/api/news?id=8ceafd18b9e0a5a012c58f90a781c826b7b5afa47a10a9dcda217badb369f2b2"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approves Pembrolizumab For Her2 Positive Gastric Or Gastroesophageal Junction Adenocarcinoma Expressing Pd-L1",
    "summary": "FDA: * FDA: APPROVES PEMBROLIZUMAB FOR HER2 POSITIVE GASTRIC ORGASTROESOPHAGEAL JUNCTION ADENOCARCINOMA EXPRESSING PD-L1Further company coverage: ...",
    "url": "https://finnhub.io/api/news?id=9e985ca4befde49dc7cdec5098eb233e8109f5c4f5687d049945981afb614db8",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742393397,
      "headline": "FDA Approves Pembrolizumab For Her2 Positive Gastric Or Gastroesophageal Junction Adenocarcinoma Expressing Pd-L1",
      "id": 133257524,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "FDA: * FDA: APPROVES PEMBROLIZUMAB FOR HER2 POSITIVE GASTRIC ORGASTROESOPHAGEAL JUNCTION ADENOCARCINOMA EXPRESSING PD-L1Further company coverage: ...",
      "url": "https://finnhub.io/api/news?id=9e985ca4befde49dc7cdec5098eb233e8109f5c4f5687d049945981afb614db8"
    }
  },
  {
    "ts": null,
    "headline": "Actinium Pharmaceuticals launches clinical trial for Actimab-A in combination",
    "summary": "Actinium Pharmaceuticals (ATNM) announced a clinical program comprising of trials studying Actimab-A in combination with either Keytruda – pembrolizumab -or Opdivo – nivolumab – which are blockbuster immunotherapies known as PD-1 inhibitors which are approved in multiple solid tumor indications. Keytruda, developed and commercialized by Merck (MRK) and Opdivo developed and commercialized by Bristol Myers Squibb (BMY), collectively generated $38.8B in sales in 2024 across several solid tumor canc",
    "url": "https://finnhub.io/api/news?id=9c073200cbeb7b0642f656dff7e5c20a16fe4344b3370ff66e4e87f269317ce6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742386292,
      "headline": "Actinium Pharmaceuticals launches clinical trial for Actimab-A in combination",
      "id": 133324749,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Actinium Pharmaceuticals (ATNM) announced a clinical program comprising of trials studying Actimab-A in combination with either Keytruda – pembrolizumab -or Opdivo – nivolumab – which are blockbuster immunotherapies known as PD-1 inhibitors which are approved in multiple solid tumor indications. Keytruda, developed and commercialized by Merck (MRK) and Opdivo developed and commercialized by Bristol Myers Squibb (BMY), collectively generated $38.8B in sales in 2024 across several solid tumor canc",
      "url": "https://finnhub.io/api/news?id=9c073200cbeb7b0642f656dff7e5c20a16fe4344b3370ff66e4e87f269317ce6"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co (MRK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit",
    "summary": "LOS ANGELES, March 19, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Merck & Co have opportunity to lead the securities fraud class action...",
    "url": "https://finnhub.io/api/news?id=15d05dc8938dd10b6cdf4b445a51365de3061bfb5d6d32c435e7e558f0d38cb7",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742385671,
      "headline": "Merck & Co (MRK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit",
      "id": 133249585,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "LOS ANGELES, March 19, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Merck & Co have opportunity to lead the securities fraud class action...",
      "url": "https://finnhub.io/api/news?id=15d05dc8938dd10b6cdf4b445a51365de3061bfb5d6d32c435e7e558f0d38cb7"
    }
  },
  {
    "ts": null,
    "headline": "Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy",
    "summary": "Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada approved KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with carboplatin and paclitaxel, followed by KEYTRUDA® as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. The approval is based on data from the Phase 3 KEYNOTE-868 trial, also known as NRG-GY018, which demonstrated statistically significant improvemen",
    "url": "https://finnhub.io/api/news?id=cd2f244a377a96350cab5c817ea89309f9b9077332517740ffbbccf635e2c7fd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742382000,
      "headline": "Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy",
      "id": 133324750,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada approved KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with carboplatin and paclitaxel, followed by KEYTRUDA® as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. The approval is based on data from the Phase 3 KEYNOTE-868 trial, also known as NRG-GY018, which demonstrated statistically significant improvemen",
      "url": "https://finnhub.io/api/news?id=cd2f244a377a96350cab5c817ea89309f9b9077332517740ffbbccf635e2c7fd"
    }
  },
  {
    "ts": null,
    "headline": "Merck Data at ACC.25 Highlight Innovative Advancements and Commitment to Improving Outcomes for People Living with Cardiovascular Disease",
    "summary": "RAHWAY, N.J., March 19, 2025--Merck Data at ACC.25 Highlight Innovative Advancements and Commitment to Improving Outcomes for People Living with Cardiovascular Disease",
    "url": "https://finnhub.io/api/news?id=ea2417564fffba57f541ae35529a5d974760d9f87a067472b46959cd7d344ad8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742381100,
      "headline": "Merck Data at ACC.25 Highlight Innovative Advancements and Commitment to Improving Outcomes for People Living with Cardiovascular Disease",
      "id": 133324751,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., March 19, 2025--Merck Data at ACC.25 Highlight Innovative Advancements and Commitment to Improving Outcomes for People Living with Cardiovascular Disease",
      "url": "https://finnhub.io/api/news?id=ea2417564fffba57f541ae35529a5d974760d9f87a067472b46959cd7d344ad8"
    }
  },
  {
    "ts": null,
    "headline": "Health Canada Approves KEYTRUDA For The Treatment Of Adult Patients With Primary Advanced Or Recurrent Endometrial Carcinoma, In Combination With Carboplatin And Paclitaxel And Then Continued As Monotherapy",
    "summary": "Merck & Co Inc: * HEALTH CANADA APPROVES KEYTRUDA® FOR THE TREATMENT OFADULTPATIENTS WITH PRIMARY ADVANCED OR RECURRENT ENDOMETRIALCARCINOMA, IN COMBINATION WITH CARBOPLATIN AND...",
    "url": "https://finnhub.io/api/news?id=e979c9f26d69626eece94fb61b0109447babb2f6680fed4d6a5b9569ea98c1d6",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742368465,
      "headline": "Health Canada Approves KEYTRUDA For The Treatment Of Adult Patients With Primary Advanced Or Recurrent Endometrial Carcinoma, In Combination With Carboplatin And Paclitaxel And Then Continued As Monotherapy",
      "id": 133239253,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck & Co Inc: * HEALTH CANADA APPROVES KEYTRUDA® FOR THE TREATMENT OFADULTPATIENTS WITH PRIMARY ADVANCED OR RECURRENT ENDOMETRIALCARCINOMA, IN COMBINATION WITH CARBOPLATIN AND...",
      "url": "https://finnhub.io/api/news?id=e979c9f26d69626eece94fb61b0109447babb2f6680fed4d6a5b9569ea98c1d6"
    }
  }
]